The FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes, making it the second such agent cleared in the US and …
The FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes, making it the second such agent cleared in the US and …
Donanemab is now infused in a Mexican public hospital. Lilly’s 2026 target: 30 patients — the gap between innovation and the system, in one number.
Eli Lilly agreed to acquire Merida Biosciences for up to $2.9 billion, adding a precision antibody-targeting platform to its immunology pipeline as the company’s 2026 acquisition total surpasses $31 billion.
Positive Phase 2b results for elecoglipron and aleniglipron confirm that small-molecule oral GLP-1 receptor agonists can deliver meaningful weight loss without food or fluid restrictions, intensifying competition in obesity and …
CVS Caremark will cover Eli Lilly’s oral GLP-1 pill Foundayo from June 1 and restore Zepbound as a preferred option by October 1, completing Lilly’s access across all three major …
ANS mandates private-plan coverage for olaparib in BRCA-mutant prostate cancer, osimertinib plus chemotherapy in EGFR+ lung cancer, and lebriquizumab in severe atopic dermatitis following a price concession.
You must be logged in to post a comment.